Benign breast dysplasia and combined oral contraceptives


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To study current ideas on the role of combined oral contraceptives (COC) in the development of breast cancer. Material and methods. Key words were used to f ind sources on this topic in international databases; 24 sources were selected. Results. There is an update on the role of COC in the development of breast cancer, on the need to individually choose COC having an antiproliferative gestagenic component (dienogest, drospirenone) and on the possibilities to adjust an estrogen dose, without needlessly changing completely COC (ethinyl estradiol 30 or 20 pg), antirecurrent therapy, particularly in women after breast surgery (sector resection) or invasive diagnosis (puncture, biopsy). Conclusion. The timely preclinical diagnosis and targeted prevention of tumors, individual choice of COC, and a possibility to adjust an estrogen dose, as well as antirecurrent therapy are present-day actual measures to reduce female morbidity rates and to improve survival and quality of life.

全文:

受限制的访问

作者简介

Vladislava Novikova

Kuban State Medical University

Email: vladislavan@mail.ru
MD, professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of Postgraduate Education

Grigory Penzhoyan

Kuban State Medical University; Territorial Clinical Hospital Two

Email: pga05@mail.ru
MD, professor, Head of the Department of Obstetrics, Gynecology and Perinatology, Department of Obstetrics, Gynecology and Perinatology, Faculty of Postgraduate Education

Oleg Fedorovich

Kuban State Medical University

Email: olegfedo@mail.ru
MD, professor of the Department of Obstetrics, Gynecology and Perinatology, Faculty of postgraduate Education

参考

  1. Seetharam P., Rodrigues G. Benign breast disorders: An insight with a detailed literature review. WebmedCentral Breast. 2015; 6(1): WMC004806.
  2. Приказ Минздравсоцразвития России № 808н от 2 октября 2009 г. «Об утверждении Порядка оказания акушерско-гинекологической помощи». [Order of the Health Ministry of Russia №808n dated October 2, 2009. „On approval of the provision of obstetric care.” (in Russian)]
  3. Приказ Министерства здравоохранения Российской Федерации (Минздрав России) от 1 ноября 2012 г. № 572н «Об утверждении Порядка оказания медицинской помощи по профилю акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)». [The Russian Federation Ministry of Health Order (Ministry of Health of Russia) dated November 1, 2012 № 572n „On approval of the provision of medical care on the profile of obstetrics and gynecology (except for the use of assisted reproductive technologies).” (in Russian)]
  4. Дьячкова С.Ю. Патофизиология опухолевого роста. Методическая разработка. Волгоград; 2012. 19 с. [Dyachkova S.Yu. Pathophysiology of tumor growth. Tutorial. Volgograd; 2012. 19 p. (in Russian)]
  5. Франк Г.А., Данилова Н.В., Андреева Ю.Ю., Нефедова Н.А. Классификация опухолей молочной железы ВОЗ 2012 года. Архив патологии. 2013; 75(2): 53-63. [Frank G.A., Danilova N.V., Andreyeva Yu.Yu., Nefedova N.A. WHO classification of breast tumors in 2012. Archives of Pathology. 2013; 75(2): 53-63. (in Russian)]
  6. Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., van de Vijver M.J., eds. WHO classification of tumours of the breast. IARC/World health organization classification of tumours. Lyon, France: WHO Press; 2012.
  7. Савельева Г.М., Сухих Г.Т., Манухин И.Б., ред. Гинекология. Национальное руководство. Краткое издание. М.: ГЭОТАР-Медиа; 2013. 704с. [Savelieva G.M., Sukhikh G.T., Manukhin I.B., ed. Gynecology. National guidance. Brief Edition. Moscow: GEOTAR-Media; 2013. 704 p. (in Russian)]
  8. Харченко В.П., Рожкова Н.И., ред. Маммология. Национальное руководство. М.: ГЭОТАР-Медиа; 2009. 328с. [Kharchenko V.P., Rozhkova N.I., ed. Mammalogy: national guidance. Moscow: GEOTAR-Media. 2009; 328 p. (in Russian)]
  9. Morrow M., Schnitt S. J., Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat. Rev. Clin. Oncol. 2015; 12(4): 227-38. doi: 10.1038/nrclinonc.2015.8.
  10. Socolov D., Anghelache I., Ilea C., Socolov R., Carauleanu A. Benign breast disease and the risk of breast cancer in the next 15 years. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2015; 119(1): 135-40.
  11. Беспалов В.Г., Травина М.Л. Фиброзно-кистозная болезнь и риск рака молочной железы (обзор литературы). Опухоли женской репродуктивной системы. 2015; 11(4): 58-70. [Bespalov V.G., Travina M.L. Fibrocystic disease and the risk of breast cancer (review). Opuholi zhenskoy reproduktivnoy sistemyi. 2015; 11(4): 58-70. (in Russian)]
  12. Пароконная А.А. Рак молочной железы и беременность. Современное состояние проблемы. Практическая онкология. 2009; 10(4): 179-83. [Parokonnaya A.A. Breast cancer and pregnancy. The current state of the problem. Prakticheskaya onkologiya. 2009; 10(4): 179-183. (in Russian)]
  13. Hickey M., Peate M., Saunders C.M., Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum. Reprod. Update. 2009; 15(3): 323-39.
  14. Colditz G. A., Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J. Clin. 2014; 64(3): 186-94.
  15. Salzman B., Fleegle S., Tully A.S. Common breast problems. Am. Fam. Physician. 2012; 86(4): 343-9.
  16. Bethea T.N., Rosenberg L., Hong C.C., Troester M.A., Lunetta K.L., Bandera E.V. et al. A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American Breast Cancer Epidemiology and Risk Consortium. Breast Cancer Res. 2015; 17: 22.
  17. Brohet R.M., Goldgar D.E., Easton D.F., Antoniou A.C., Andrieu N., Chang-Claude J. et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEOHEBON, and the IBCCS Collaborating Group. J. Clin. Oncol. 2007; 25(25): 3831-6. doi: 10.1200/JCO.2007.11.1179.
  18. Beaber E.F., Buist D.S., Barlow W.E., Malone K.E., Reed S.D., Li C.I. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res. 2014; 74(15): 4078-89. doi: 10.1158/0008-5472.CAN-13-3400.
  19. Подзолкова Н.М., Коренная В.В. Онкопротективные эффекты гормональных контрацептивов. Гинекология. 2012; 14(1): 28-33. [Podzolkova N.M., Korennaya V.V. Oncoprotective effects of hormonal contraceptives. Ginekolgiya. 2012; 14(1): 28-33. (in Russian)]
  20. WHO medical eligibility criteria wheel for contraceptive use - 2015 update. 1. Contraception - methods. 2. Family Planning Services - methods. 3. Eligibility Determination - standards. Switzerland; 2015. 8p
  21. Murshid Kh.R. A review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options. J. Taibah Univ. Med. Sci. 2011; 6(1): 1-18.
  22. Сотникова Л.С., Удут Е.В., Тонких О.С. Применение Визанны при эндометриозе в сочетании с доброкачественной патологией молочных желез. Проблемы репродукции.2013; 19(4): 44-50. [Sotnikova L.S., Udut E.V., Tonkih O.S. Application of Visanna with endometriosis in combination with benign breast pathologies. Problemyi reproduktsii.2013; 19(4): 44-50. (in Russian)]
  23. Унанян А.Л., Демура С.А., Гаспарян А.А., Аракелов С.Э., Полонская Л.С., Гуриев Т.Д., Алимов В.А., Бабурин Д.В., Коссович Ю.М. Эндометриоз и комбинированная гормональная контрацепция: преимущества и риски. Эффективная фармакотерапия. 2015; 19: 10-5. [Unanyan A.L., Demura S.A. Gasparyan A.A. Arakelov S.E., Polonskaya L.S. , Guriev T.D., Alimov V.A., Baburin D.V., Kossovich Yu.M. Endometriosis and combined hormonal contraception: benefits and risks. Effektivnaya farmakoterapiya. 2015; 19: 10-5. (in Russian)]
  24. Stewart M., Black K. Choosing a combined oral contraceptive pill. Aust. Prescr. 2015; 38(1): 6-11.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##